Dan Ivan, country head of Sanofi-Aventis, the largest player on the Romanian pharmaceutical market, says the group could relocate production of several drugs to its Bucharest plant, which became part of the group's portfolio when it acquired Czech company Zentiva. The first stage is likely to include four products, but the number is not final. They are antibiotics and antihypertensive drugs, but the company had also previously announced plans to manufacture a urology drug aimed exclusively at the German market. "Those in charge of industrial operations in Prague (Zentiva's headquarters) plan to use more of the capacity of the Romanian production facility. There are further drugs whose production will be transferred to the former Sicomed plant within the group. We will start with a series of four, but this is not relevant because we are dependent on the volumes of sales of these products," said Dan Ivan, 51, who is also chairman of Zentiva's Board of Directors. The overall production capacity of the Romanian plant is 100 million units, but only around 64-70% of it is used. According to market analysis and research company Cegedim, Sanofi-Aventis (Zentiva included) posted 815.7 million RON (194 million euros) in sales on the Romanian market and had a 10.1% market share. "I think we could even be congratulated if we preserve 2009's level, with differences from one product to another," Ivan added. Dan Ivan, country head of Sanofi-Aventis, the largest player on the Romanian pharmaceutical market, says the group could relocate production of several drugs to its Bucharest plant, which became part of the group's portfolio when it acquired Czech company Zentiva. The first stage is likely to include four products, but the number is not final. They are antibiotics and antihypertensive drugs, but the company had also previously announced plans to manufacture a urology drug aimed